Paper Details

  1. Home
  2. Paper Details

[Comparison of the effect of a selective and a nonselective beta receptor blocker on the ischemic ST segment, lung function and stress-induced decrease in blood glucose].

Author: BlasiniR, BrügmannU

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Betaxolol, a cardioselective beta-blocking agent, was as effective as nadolol, a non-selective agent, in reducing ST-segment depression in patients with stable exercise angina pectoris.
Paper Details　
Original Abstract of the Article :
This study was designed to compare the antihypertensive and anti-ischemic effects of the newly developed cardioselective beta-blocking agent, betaxolol, with the non-selective agent, nadolol, both of which have hydrophilic long acting properties, over a period of 48 hours. Additionally, the study wa...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/2870014

データ提供：米国国立医学図書館（NLM）

Beta Blockers: A Journey Through the Desert of Cardiovascular Health

Beta blockers, a mainstay in the treatment of cardiovascular disease, are as diverse as the plant life found in a desert oasis, each type offering unique benefits and potential drawbacks. This study compares the effects of two beta blockers, betaxolol (selective) and nadolol (nonselective), on various cardiovascular parameters. Researchers meticulously measured ischemic ST-segment depression, lung function, and stress-induced blood glucose changes in patients with coronary artery disease (CAD). They found that both betaxolol and nadolol effectively reduced ischemic ST-segment depression, indicating their ability to protect the heart from damage caused by reduced blood flow. However, betaxolol, the selective beta blocker, showed a lesser impact on pulmonary function, suggesting a potential advantage for patients with respiratory concerns.

A Careful Choice: Selecting the Right Beta Blocker

This study, like a desert traveler carefully choosing a path through a diverse landscape, highlights the importance of selecting the right beta blocker for individual needs. The researchers' findings suggest that while both betaxolol and nadolol effectively manage cardiovascular symptoms, betaxolol may offer a more favorable profile for patients with respiratory concerns.

Health Benefits and Daily Application

If you're taking beta blockers, it's crucial to work closely with your doctor to ensure you're receiving the most appropriate treatment for your specific needs. Regular monitoring and open communication with your healthcare provider are essential for optimizing your health outcomes.

Dr. Camel's Conclusion

This study provides valuable insights into the diverse effects of beta blockers on cardiovascular health. Just as a camel navigates a desert landscape with careful attention to terrain and resources, healthcare professionals must carefully select the right beta blocker for each individual, considering their unique health profile and needs.

Date :
  1. Date Completed 1986-04-28
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

2870014

DOI: Digital Object Identifier

2870014

SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.